Abstract
Sotorasib is a first-in-class small molecule that specifically and irreversibly inhibits KRASG12C. The phase 1/2 CodeBreaK 100 trial evaluated sotorasib in patients with pretreated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C. In the registrational phase 2 part, sotorasib showed an objective response rate (ORR) of 37.1% and a median progression-free survival (PFS) of 6.8 months. Here, we report on the activity of sotorasib in patients with treated brain metastases (BM).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
